<?xml version="1.0" encoding="UTF-8"?>
<ref id="cit0051">
 <label>51.</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Duggan</surname>
   <given-names>BM</given-names>
  </string-name>, 
  <string-name>
   <surname>Foley</surname>
   <given-names>KP</given-names>
  </string-name>, 
  <string-name>
   <surname>Henriksbo</surname>
   <given-names>BD</given-names>
  </string-name>, 
  <string-name>
   <surname>Cavallari</surname>
   <given-names>JF</given-names>
  </string-name>, 
  <string-name>
   <surname>Tamrakar</surname>
   <given-names>AK</given-names>
  </string-name>, 
  <string-name>
   <surname>Schertzer</surname>
   <given-names>JD</given-names>
  </string-name>. 
  <article-title>Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia</article-title>. 
  <source>
   <italic toggle="yes">Sci Rep</italic>
  </source>. 
  <year>2017</year>;
  <volume>7</volume>(
  <issue>1</issue>):
  <fpage>1578</fpage>. doi:
  <pub-id pub-id-type="doi">10.1038/s41598-017-01822-0</pub-id>
  <pub-id pub-id-type="pmid">28484277</pub-id>
 </mixed-citation>
</ref>
